© Springer International Publishing Switzerland 2017
Hardik P. Amin and Joseph L. Schindler (eds.)Vascular Neurology Board Review10.1007/978-3-319-39605-7_1919. Pharmacology
(1)
Assistant Professor of Neurology, Yale University School of Medicine, Associate Director, Vascular Neurology Fellowship, Yale-New Haven Hospital, New Haven, Connecticut, USA
(2)
Associate Professor of Neurology and Neurosurgery, Yale University School of Medicine, Director, Acute Stroke and TeleStroke Services, Director, Vascular Neurology Fellowship, Yale-New Haven Hospital, New Haven, Connecticut, USA
Abbreviations
ACE-I
Angiotensin-converting enzyme inhibitor
ADP
Adenosine diphosphate
AF
Atrial fibrillation
ARB
Angiotensin II receptor blocker
ASA
Acetylsalicylic acid
AV
Atrioventricular
BB
Beta-blocker
CAMP
Cyclic adenosine monophosphate
CCB
Calcium channel blocker
CHF
Congestive heart failure
CK
Creatine kinase
COX
Cyclooxygenase
DM
Diabetes mellitus
GI
Gastrointestinal
HCTZ
Hydrochlorothiazide
HDL
High-density lipoprotein
HMGCoA
3-Hydroxy-3-methylglutaryl-coenzyme A
HTN
Hypertension
ICP
Intracranial pressure
INR
International normal ratio
LDL
Low-density lipoprotein
LFT
Liver function enzymes
LMWH
Low molecular weight heparin
PPI
Proton pump inhibitor
TG
Triglycerides
TPA
Tissue plasminogen activator
Introduction
The management of patients with cerebrovascular disease has become complex given the severity of concomitant medical comorbidities. An understanding of the clinical indication and pharmacological basis for stroke therapeutics is critical. Many of these treatments are initiated by neurologists shortly after an acute stroke for prompt secondary prevention. Additionally, many vascular neurologists will oversee therapeutics used to treat thrombosis, hypertension , and hyperlipidemia in the outpatient setting along with cardiologists and internists.
Antihypertensives
-
Diuretics: act on kidneys to increase Na excretion
-
Standard first-line therapy for essential HTN
-
Thiazides: best used in mild to moderate HTN
-
HCTZ (watch for hypokalemia)
-
-
Loop diuretics: severe HTN
-
Furosemide
-
-
K-sparing: spironolactone, triamterene, amiloride
-
SE: hypokalemia, hyperlipidemia, hyper best used in glycemia
-
-
Beta-blockers (BB)
-
Reduce cardiac output, inhibit renin release, may decrease adrenergic outflow, and mask symptoms of hypoglycemia
-
More effective in whites than African Americans, and in younger patients than older
-
Nonselective
-
Labetalol: combined alpha- and beta-blockade, β1 + β2 > α1 receptor antagonist
-
Propranolol
-
-
Cardioselective (β1 receptor antagonists)
-
Metoprolol
-
Atenolol
-
Esmolol: rapid acting, short duration
-
-
Adverse effects
-
Abrupt withdrawal: tachycardia, nervousness, hypertension
-
Use with caution in asthmatics, recent cocaine use (due to postulated un-opposed α effect, exacerbating coronary vasospasm)
-
May increase triglycerides, decrease HDL
-
-
-
Alpha blockers
-
Competitively block alpha-1 receptors in arterioles and venules
-
Prazosin, doxazosin, terazosin
-
Adverse effects: cause significant vasodilation, risk of postural hypotension, orthostasis, syncope
Stay updated, free articles. Join our Telegram channel
-

Full access? Get Clinical Tree

